The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease

The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease

Aim: The Salford Lung Study (SLS) in chronic obstructive pulmonary disease (COPD) was a randomised controlled trial evaluating the effectiveness and safety of initiating fluticasone furoate/vilanterol (FF/VI) 100/25 µg versus continuing usual care (UC) in patients with COPD and a history of exacerba...

Full description

Bibliographic Details
Main Authors:	Nawar Diar Bakerly, Dominy Browning, Isabelle Boucot, Jodie Crawford, Sheila McCorkindale, Norman Stein, John P. New
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-03-01
Series:	Therapeutic Advances in Respiratory Disease
Online Access:	https://doi.org/10.1177/17534666211001013

Similar Items

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
by: Covelli H, et al.
Published: (2015-12-01)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
by: Peter R. Bremner, et al.
Published: (2018-01-01)

The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience
by: Timothy E. Albertson, et al.
Published: (2016-02-01)

Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
by: Lal C, et al.
Published: (2016-12-01)

Effect of once-daily fluticasone furoate/vilanterol vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial
by: Francois Maltais, et al.
Published: (2020-10-01)

A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD
by: Bhatt SP, et al.
Published: (2017-01-01)

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
by: Molino A, et al.
Published: (2018-06-01)

Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD
by: Caramori G, et al.
Published: (2014-02-01)

Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy
by: Albertson TE, et al.
Published: (2016-12-01)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
by: Sally Worsley, et al.
Published: (2019-11-01)

Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS
by: Vallejo-Aparicio LA, et al.
Published: (2018-09-01)

Triple Therapy of Fluticasone Furoate, Umeclidinium, Vilanterol- A Compelling Choice in Severe Chronic Obstructive Pulmonary Disease
by: B Jagan Nathan, et al.
Published: (2021-02-01)

Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial
by: George Bardsley, et al.
Published: (2018-07-01)

Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort Study
by: Daniel Dedman, et al.
Published: (2019-04-01)

Impact of socioeconomic status on participation and outcomes in the Salford Lung Studies
by: Rupert Jones, et al.
Published: (2020-03-01)

Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
by: Ryo Atsuta, et al.
Published: (2018-10-01)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
by: Sandeep Bansal, et al.
Published: (2021-05-01)

Efficacy of Mometasone Furoate and Fluticasone Furoate on Persistent Allergic Rhinoconjunctivitis
by: W. Hamizan Aneeza M.S., et al.
Published: (2013-09-01)

Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma
by: Roberto W. Dal Negro, et al.
Published: (2018-09-01)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
by: Harsha H Kariyawasam, et al.
Published: (2010-06-01)

Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects
by: Mario Malerba, et al.
Published: (2018-03-01)

Fluticasone furoate: A new intranasal corticosteroid
by: R Kumar, et al.
Published: (2012-01-01)

Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial
by: Furuhashi K, et al.
Published: (2019-09-01)

New combination treatments in the management of asthma: focus on fluticasone/vilanterol
by: Tan LD, et al.
Published: (2014-05-01)

Fluticasone furoate nasal spray in the treatment of allergic rhinitis
by: Pedro Giavina-Bianchi, et al.
Published: (2008-04-01)

Real-world efficacy and problems of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) in Japanese patients with asthma
by: Akira Umeda, et al.
Published: (2019-01-01)

Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial
by: Oliver Amanda, et al.
Published: (2012-06-01)

A Patient Preference Study that Evaluated Fluticasone Furoate and Mometasone Furoate Nasal Sprays for Allergic Rhinitis
by: Anahi Yanez M.D., et al.
Published: (2016-10-01)

Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo.
by: Nan Zhang, et al.
Published: (2014-01-01)

Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis
by: Maria Doulaptsi, et al.
Published: (2021-09-01)

Safety data in randomised real-world evidence studies: Salford Lung Study learnings
by: Catherine Harvey, et al.
Published: (2021-05-01)

Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study
by: Hozawa S, et al.
Published: (2021-07-01)

Patient and healthcare professional experiences of the Salford Lung Studies: qualitative insights for future effectiveness trials
by: Kim Gemzoe, et al.
Published: (2020-09-01)

In vitro Antibacterial Activity of Mometasone Furoate, Fluticasone Propionate and Fluticasone Furoate Nasal Preparations Against Streptococcus pneumoniae, Hemophilus influenzae, Streptococcus viridans, Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli
by: Philip Lance A. Liu, et al.
Published: (2010-06-01)

A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD
by: Courtney Crim, et al.
Published: (2020-05-01)

Patient perspectives on fluticasone–vilanterol versus other corticosteroid combination products for the treatment of asthma
by: Bollmeier SG, et al.
Published: (2016-05-01)

Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate
by: Högger Petra, et al.
Published: (2007-07-01)

Comparative study of the efficacy and safety of intranasal azelastine hydrochloride and fluticasone furoate in the treatment of allergic rhinitis
by: Nandish Chennakeshavaraju, et al.
Published: (2020-01-01)

Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial
by: Jacques Loretta, et al.
Published: (2011-10-01)